VJHemOnc is committed to improving our service to you

Share this video  

VJHemOnc is committed to improving our service to you

EHA 2022 | Results of QuANTUM-First: quizartinib vs placebo plus intensive chemotherapy in FLT3-ITD+ AML

Harry Erba, MD, PhD, Duke University, Durham, NC, discusses the rationale, design and results of QuANTUM-First (NCT02668653), a Phase III study comparing the efficacy of quizartinib vs placebo, both administered in combination with induction and consolidation chemotherapy in patients with FLT3-ITD+ acute myeloid leukemia (AML). The study met its primary endpoint of overall survival (OS) and showed that treatment with quizartinib was tolerable and significantly reduced relapse risk in patients up to 75 years old. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.

Disclosures

Consultancy: Daiichi Sankyo, BMS

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter